Oral vs. Injectable GLP-1 Options: What to Ask
Compare GLP-1 tablets and weekly injections on how each is taken, what each label says, what trials measured, and what to ask a clinician.
On this page
The short answer
As of September 2026, two GLP-1 tablets carry FDA-approved labels for weight management: Wegovy tablets (semaglutide) and Foundayo (orforglipron). The main practical difference is how you take them: Wegovy tablets have to be taken on an empty stomach with a wait before eating, Foundayo can be taken with or without food, and Wegovy injection is a once-weekly shot. The trials were run separately, so their weight-change numbers should not be ranked against each other.
Which oral and injectable GLP-1 options exist for weight management?
Two tablets have FDA-approved weight-management labels as of this check, and both sit alongside injections. The Wegovy label now covers Wegovy injection and Wegovy tablets, both semaglutide. 1 Foundayo is a once-daily orforglipron tablet with its own label, listing initial U.S. approval in 2026. 2 Tirzepatide (Zepbound) is discussed in our semaglutide vs. tirzepatide comparison; this article does not cover its label.
Both labels describe use with a reduced-calorie diet and increased physical activity, in adults with obesity or with overweight and at least one weight-related condition. Neither label recommends combining the product with another GLP-1 medicine. 1 2 For orientation on the class, start with our GLP-1 guide.
How does taking a tablet differ from taking an injection?
The routine differs more than the goal. This table summarizes what each label says about administration. It describes the labels, not instructions for you; your prescriber and your product's instructions decide how you take yours.
| Wegovy injection | Wegovy tablets | Foundayo tablets | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Orforglipron |
| How often | Once a week | Once a day | Once a day |
| Food and drink | With or without meals | Empty stomach, morning, with up to 4 ounces of plain water; then wait at least 30 minutes before food, drinks, or other oral medicines | With or without food |
| Form | Injected under the skin | Swallowed whole | Swallowed whole |
Tablets remove the injection. They add a daily habit, and for Wegovy tablets a morning routine with a built-in wait. An injection removes the daily habit. Neither is easier for everyone, so ask which fits your mornings, your other medicines, and how you feel about needles.
What did the trials measure, and can you compare them?
You cannot rank these products from their labels. Each was studied in a different trial, with different lengths, populations, and analysis methods.
| Product | Trial length | Average change in body weight vs. placebo group |
|---|---|---|
| Wegovy injection (usual maintenance amount) | 68 weeks | −14.9% vs. −2.4% |
| Wegovy tablets (labeled maintenance amount) | 64 weeks | −13.6% vs. −2.4% |
| Foundayo, lowest studied maintenance group | 72 weeks | −7.4% vs. −2.1% |
| Foundayo, highest studied group | 72 weeks | −11.1% vs. −2.1% |
These rows come from adults without type 2 diabetes. Where trials also enrolled people with type 2 diabetes, average changes were smaller: Wegovy injection −9.6% and Foundayo −5.1% to −9.6%, depending on dose group. The Wegovy tablet trial excluded people with type 2 diabetes. 1 2
Three cautions apply. Averages describe a study group and do not predict your result. The trials were separate, so a gap between two rows may reflect differences in design rather than in the medicines. And the Foundayo figures are reported by dose group, so the range depends on which group you look at. 2 Ask a provider quoting a percentage which trial it came from and how closely that group resembles you.
Which safety limits apply to both formats?
Both tablet labels share the core exclusions of the injection labels. Each is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and with known hypersensitivity to the medicine or its ingredients (Foundayo's label specifies serious hypersensitivity). 1 2
Both labels also warn about pancreatitis, gallbladder disease, and gastrointestinal reactions that can be severe, and both list nausea, diarrhea, vomiting, and constipation among common reactions. 1 2 If you develop severe or persistent stomach pain, repeated vomiting, or signs of an allergic reaction, contact a clinician or seek urgent care rather than waiting for a scheduled visit. Our side-effects article explains what to watch for.
The Foundayo label differs on one point of wording: its boxed warning notes that orforglipron did not produce tumors in rodents, but says the human relevance of thyroid C-cell findings with GLP-1 receptor activity has not been determined. 2 It still carries the MTC/MEN 2 contraindication.
How can these medicines affect other pills?
Wegovy injection and tablets slow stomach emptying, which can affect how other oral medicines are absorbed. Foundayo carries this warning too. 1 2
The evidence differs by product and format. The Wegovy label reports a 33% increase in levothyroxine exposure in a study with oral semaglutide; that finding is specific to the tablet study. It also reports no effect on oral-medicine absorption in studies using semaglutide 1 mg once-weekly injection. 1
If you take thyroid medicine or any pill with a narrow safety margin, ask before starting whether anything needs extra monitoring.
Hormonal contraception matters too. The Foundayo label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase. 2 Raise this early if it applies to you. If you are in perimenopause, our perimenopause article covers how weight care and midlife symptoms fit into one appointment.
What about compounded tablets or injections?
Compounded products are not the approved products, and trial results for the approved products do not carry over to them. FDA states that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before they are marketed. 3 If you are offered a compounded oral or injectable preparation, ask why it suits you and what the approved alternative would involve. See compounded vs. brand-name GLP-1 medicines.
What should you ask your clinician?
Use this checklist to turn the comparison into a conversation.
- Which exact product and format are you recommending, and why for me?
- What does the label require for taking it, and does that fit my mornings and my other medicines?
- Which of my medicines could be affected by slower stomach emptying?
- Does anything in my history, including thyroid conditions, pancreas or gallbladder problems, or planned procedures, change the options?
- Am I using oral contraception, and does this product need a backup?
- What is the full monthly cost, including care and follow-up? I will compare that in writing. Prices change often, so this article does not quote them; our GLP-1 cost guide shows how to compare.
- What happens if I cannot tolerate this format, and how easy is it to change?
Common questions
Is a pill automatically better than an injection?
No. A pill removes the needle and adds a daily routine. The labels and trials differ, and neither format is better for everyone. The decision rests on your health, your routine, and what your clinician recommends.
Can I switch between formats on my own?
No. Changing product or format is a prescribing decision. Ask your clinician how a switch would work and what monitoring it would need.
Do the trials show the same result for tablets and injections?
They show different results in different trials. The evidence does not settle which format works better for you, and these separate trials cannot answer that.
References
- Wegovy (semaglutide) injection and tablets: Prescribing Information — Novo Nordisk
- Foundayo (orforglipron) tablets: Prescribing Information — Eli Lilly and Company
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
For your information. This article provides general education and does not replace medical advice or an individual evaluation. Talk to your clinician before starting, changing, or stopping treatment. Compounded medications are not FDA-approved.